U.S. markets close in 2 hours 53 minutes

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
3.8350+0.1150 (+3.09%)
A partir del 01:07PM EDT. Mercado abierto.

Pacific Biosciences of California, Inc.

1305 O’Brien Drive
Menlo Park, CA 94025
United States
650 521 8000
https://www.pacb.com

Sector(es)Healthcare
IndustriaMedical Devices
Empleados a tiempo completo796

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Christian O. Henry M.B.A.President, CEO & Director1.1MN/D1968
Ms. Susan G. KimChief Financial Officer564.87kN/D1977
Mr. Mark Van OeneChief Operating Officer772.11kN/D1973
Mr. Jeff EidelChief Commercial Officer435.62kN/D1977
Dr. Stephen Turner Ph.D.Co-Founder341.25kN/D1968
Ms. Michele Farmer CPAVP & Chief Accounting OfficerN/DN/D1980
Trevin RardHead of Investor RelationsN/DN/DN/D
Dr. Brett Atkins J.D., Ph.D.General Counsel & Corporate SecretaryN/DN/DN/D
Ms. Natalie WelchChief People OfficerN/DN/DN/D
Dr. Denis Zaccarin Ph.D.Senior Vice President of Research & Development510.77k4.34M1966
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Gestión corporativa

La calificación ISS Governance QuickScore de Pacific Biosciences of California, Inc. a partir del 1 de marzo de 2024 es 5. Las puntuaciones principales son Auditoría: 6; Junta: 3; Derechos del accionista: 4; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.